Linagliptin (Tradjenta) for Type 2 Diabetes — Weight & Metabolism
Unique DPP-4 inhibitor with biliary elimination requiring no dose adjustment for kidney or liver impairment, proven safe in the CARMELINA and CAROLINA trials.
Overview
Linagliptin is a unique DPP-4 inhibitor distinguished by its non-renal elimination (>80% biliary/fecal), eliminating the need for dose adjustment in any degree of renal or hepatic impairment. It has the highest DPP-4 binding potency (IC50 1nM vs 19nM for sitagliptin) and longest half-life (184 hours). CARMELINA (n=6,991) confirmed cardiovascular and renal safety in high-risk patients with T2DM and kidney disease. CAROLINA (n=6,033) showed non-inferiority to glimepiride for MACE with significantly less hypoglycemia and weight gain. Model-based meta-analysis shows equivalent HbA1c reduction of -0.81% compared to sitagliptin. Ideal for CKD patients and elderly populations. PMID: 30418475, 31530666.
Indications
- Type 2 diabetes mellitus as monotherapy or combination therapy
- Preferred DPP-4 inhibitor in patients with chronic kidney disease (no dose adjustment needed at any eGFR)
- Elderly patients with declining or fluctuating renal function
- Patients with hepatic impairment requiring DPP-4 inhibitor therapy
- Add-on to metformin, sulfonylureas, pioglitazone, or insulin
Mechanism of Action
DPP-4 enzyme rapidly degrades active GLP-1 and GIP, reducing the incretin effect that normally accounts for 50-70% of postprandial insulin secretion
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Linagliptin (Tradjenta) | 5 mg | Once daily | Single fixed dose for ALL patients regardless of renal or hepatic function |
Evidence Grade
GRADE A
Safety & Contraindications
- No dose adjustment needed for ANY degree of renal or hepatic impairment - unique among DPP-4 inhibitors
- CARMELINA confirmed no increased cardiovascular or heart failure risk in high-risk CKD patients
- CAROLINA showed significantly less hypoglycemia vs glimepiride (6.5% vs 30.9%) over 6.3 years
- Weight neutral; no clinically significant weight change vs placebo
- Rare pancreatitis risk: same class-level monitoring as other DPP-4 inhibitors
- Rare bullous pemphigoid: discontinue if blistering skin lesions develop